EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism

Karol M Pencina, Thomas G Travison, Glenn R Cunningham, A Michael Lincoff, Steven E Nissen, Mohit Khera, Michael G Miller, Panagiotis Flevaris, Xue Li, Kathleen Wannemuehler, Shalender Bhasin iD

The Journal of Clinical Endocrinology & Metabolism · 18.01.2024 · 109 (2) · 569-580

DOI: 10.1210/clinem/dgad484 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 17.08.2023. Verfasst von Karol M Pencina und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Ha…. Hauptthemen laut MEDLINE: Erectile Dysfunction, Cardiovascular Diseases, Hypogonadism. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: AbbVie, Inc, Boston Claude D. Pepper Older Americans Independence Center, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Few long-term randomized trials have evaluated the efficacy of testosterone replacement therapy (TRT) in improving sexual function and hypogonadal symptoms in men with hypogonadism and whether effects are sustained beyond 12 months.

Objective

The Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) study evaluated the effect of TRT on major adverse cardiovascular events in middle-aged and older men with hypogonadism. The Sexual Function Study, nested within the parent trial, determined testosterone's efficacy in improving sexual activity, hypogonadal symptoms, libido, and erectile function among men reporting low libido.

Methods

Among 5204 men, 45-80 years, with 2 testosterone concentrations <300 ng/dL, hypogonadal symptoms, and cardiovascular disease (CVD) or increased CVD risk enrolled in the TRAVERSE trial, 1161 with low libido were enrolled in the Sexual Function Study (587 randomized to receive 1.62% testosterone gel and 574 to placebo gel for the duration of their participation in the study). Primary outcome was change from baseline in sexual activity score. Secondary outcomes included hypogonadal symptoms, erectile function, and sexual desire.

Results

TRT was associated with significantly greater improvement in sexual activity than placebo (estimated mean [95% CI] between-group difference 0.49 [0.19,0.79] and 0.47 [0.11, 0.83] acts per day at 6 and 12 months, respectively; omnibus test P = .011); treatment effect was maintained at 24 months. TRT improved hypogonadal symptoms and sexual desire, but not erectile function, compared with placebo.

Conclusion

In middle-aged and older men with hypogonadism and low libido, TRT for 2 years improved sexual activity, hypogonadal symptoms, and sexual desire, but not erectile function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erectile DysfunctionCardiovascular DiseasesHypogonadismMaleMiddle AgedHumansAgedSexual BehaviorTestosterone

Stichwörter der Autor:innen

benefits of testosterone treatmenterectile dysfunctionhypogonadal symptomshypogonadismlow libidosexual functiontestosterone replacement therapytestosterone treatment of older men

Substanzen

Testosterone

Autor:innen und Institutionen

  • Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Marcus Institute for Aging Research, Hebrew Senior Life, Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02131, USA.
  • Departments of Medicine and Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
  • Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
  • AbbVie Inc., North Chicago, IL 60044, USA.
  • Department of Biostatistics and Medical Informatics, Statistical Data Analysis Center, University of Wisconsin-Madison, Madison, WI 53706, USA.

ORCID-Profile: Shalender Bhasin

Förderung

  • AbbVie, Inc
  • Boston Claude D. Pepper Older Americans Independence Center
  • NIA NIH HHS

Zitieren

APA

Pencina, K. M., Travison, T. G., Cunningham, G. R., Lincoff, A. M., Nissen, S. E., Khera, M., Miller, M. G., Flevaris, P., Li, X., Wannemuehler, K., & Bhasin, S. (2024). Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. The Journal of Clinical Endocrinology & Metabolism, 109(2), 569-580. https://doi.org/10.1210/clinem/dgad484

Vancouver

Pencina KM, Travison TG, Cunningham GR, Lincoff AM, Nissen SE, Khera M, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. The Journal of Clinical Endocrinology & Metabolism. 2024;109(2):569-580. doi:10.1210/clinem/dgad484

BibTeX
@article{Pencina2024,
  author = {Pencina, Karol M and Travison, Thomas G and Cunningham, Glenn R and Lincoff, A Michael and Nissen, Steven E and Khera, Mohit and Miller, Michael G and Flevaris, Panagiotis and Li, Xue and Wannemuehler, Kathleen and Bhasin, Shalender},
  title = {Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {2},
  pages = {569--580},
  doi = {10.1210/clinem/dgad484}
}
Kostenlos starten →